RT @RichardPAConway: Gordon et al. Long term safety IL23i risankizumab in psoriatic disease. Overall rates are consisten
Tweet Content
Gordon et al. Long term safety IL23i risankizumab in psoriatic disease. Overall rates are consistent with those expected for PsO/PsA populations. @RheumNow #EULAR2022 POS1023 https://t.co/yv5fFbUSI6
Show on Archive Page
On
Display in Search Results
On
PDQ
Off